Serveur d'exploration sur la maladie de Parkinson - Exploration (Accueil)

Index « ISSN » - entrée « 1435-1463 »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
14346621 < 1435-1463 < 1435-4373  Facettes :

List of bibliographic references indexed by 1435-1463

Number of relevant bibliographic references: 82.
[0-50] [0 - 20][0 - 50][50-70]
Ident.Authors (with country if any)Title
002127 (1996) M. Rodríguez [Espagne] ; M. Sabaté [Espagne] ; E. Troncoso [Espagne]Time and frequency domain analysis for the assessment of heart autonomie control in Parkinson's disease
002128 (1996) W. Kuhn [Allemagne] ; N. Heye [Allemagne] ; Th. Müller [Allemagne] ; P. Kraus [Allemagne] ; P. Klotz [Allemagne] ; B. Friedrich [Allemagne] ; L. Welter [Allemagne] ; H. Przuntek [Allemagne]The motor performance test series in Parkinson's disease is influenced by depression
002134 (1996) M. Gerlach [Allemagne] ; W. Kuhn ; Th. Müller ; P. Klotz ; H. PrzuntekSustained-release of levodopa: single dose study of a new formulation
002150 (1996) H. Braak [Allemagne] ; E. Braak [Allemagne] ; D. Yilmazer [Allemagne] ; I. De Vos [Pays-Bas] ; H. Jansen [Pays-Bas] ; J. Bohl [Allemagne]Pattern of brain destruction in Parkinson's and Alzheimer's diseases
002175 (1996) S. Hunot [France] ; V. Bernard [France] ; B. Faucheux [France] ; F. Boissière [France] ; E. Leguern [France] ; C. Brana [France] ; P. Gautris [France] ; J. Guérin [France] ; B. Bloch [France] ; Yves Agid [France] ; C. Hirsch [France]Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: A post mortem in situ hybridization study with special reference to Parkinson's disease
002180 (1996) -C. Cheng [République populaire de Chine] ; -S. Kuo [République populaire de Chine] ; -G. Chia [République populaire de Chine] ; G. Dryhurst [États-Unis]Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease
002187 (1996) H. Przuntek ; D. Welzel [Allemagne] ; M. Gerlach ; E. Blümner [Allemagne] ; W. Danielczyk [Autriche] ; -J. Kaiser ; H. Kraus ; H. Letzel [Allemagne] ; P. Riederer ; K. Überla [Allemagne]Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
002189 (1996) W. Oder [Autriche] ; T. Brücke [Autriche] ; H. Kollegger [Autriche] ; J. Spatt [Autriche] ; S. Asenbaum [Autriche] ; L. Deecke [Autriche]Dopamine D2 receptor binding is reduced in Wilson's disease: Correlation of neurological deficits with striatal123I-Iodobenzamide binding
002192 (1996) W. Kuhn [Allemagne] ; Th. Müller [Allemagne] ; M. Gerlach [Allemagne] ; E. Sofic [Allemagne] ; G. Fuchs [Allemagne] ; N. Heye [Allemagne] ; R. Prautsch [Allemagne] ; H. Przuntek [Allemagne]Depression in Parkinson's disease: biogenic amines in CSF of “de novo” patients
002209 (1996) M. Gerlach [Allemagne] ; P. Riederer [Allemagne]Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
002267 (1995) P. Laakso [Finlande] ; H. Soininen [Finlande] ; K. Partanen [Finlande] ; -L. Helkala [Finlande] ; P. Hartikainen [Finlande] ; P. Vainio [Finlande] ; M. Hallikainen [Finlande] ; T. H Nninen [Finlande] ; J. Riekkinen Sr [Finlande]Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions
002278 (1995) A. Fredriksson ; T. Archer [Suède]Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice
002299 (1995) -M. Marié [France] ; L. Barré [France] ; P. Rioux [France] ; P. Allain [France] ; B. Lechevalier [France] ; -C. Baron [France]PET imaging of neocortical monoaminergic terminals in Parkinson's disease
002305 (1995) G. Finali [Italie] ; M. Piccirilli [Italie] ; S. Rizzuto [Italie]Neuropsychological characteristics of parkinsonian patients with lateralized motor impairment
002306 (1995) -M. Wu [États-Unis, Taïwan] ; L. Murphy [États-Unis] ; C. Chiueh [États-Unis]Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity
002310 (1995) I. Bodis-Wollner [États-Unis] ; C. Borod [États-Unis] ; B. Cicero [États-Unis] ; S. Haywood [États-Unis] ; S. Raskin [États-Unis] ; L. Mylin [États-Unis] ; M. Sliwinski [États-Unis] ; A. Falk [États-Unis] ; D. Yahr [États-Unis]Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease
002312 (1995) A. Loeffler [États-Unis] ; A. Lewitt [États-Unis] ; J. Demaggio [États-Unis] ; L. Juneau [États-Unis] ; E. Milbury [États-Unis] ; R. Matson [États-Unis]Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid
002329 (1995) E. Sam [Belgique] ; N. Verbeke [Belgique]Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in parkinsonism
002334 (1995) G. Ransmayr [Autriche] ; G. Künig [Autriche] ; M. Neubauer [Autriche] ; M. Wagner [Autriche] ; M. Falk [Autriche]Effect of age and disease duration on parkinsonian motor scores under levodopa therapy
002353 (1995) A. Espino [Espagne] ; M. Calopa [Espagne] ; S. Ambrosio [Espagne] ; J. Ortolà [Espagne] ; J. Peres [Espagne] ; A. Navarro [Espagne]CSF somatostatin increase in patients with early parkinsonian syndrome
002400 (1994) S. Enochs [États-Unis] ; T. Sarna [Pologne] ; L. Zecca [Italie] ; A. Riley [Royaume-Uni] ; M. Swartz [États-Unis]The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis
002401 (1994) K. Ossowska [Pologne]The role of excitatory amino acids in experimental models of Parkinson's disease
002405 (1994) R. Rodríguez-Puertas [Espagne] ; A. Pazos [Espagne] ; J. Zarranz [Espagne] ; J. Pascual [Espagne]Selective cortical decrease of high-affinity choline uptake carrier in Alzheimer's disease: An autoradiographic study using3H-hemicholinium-3
002431 (1994) Ch. Müller [Autriche] ; S. Wenger [Autriche] ; L. Fertl [Autriche] ; E. Auff [Autriche]Initiation of visual-guided random saccades and remembered saccades in parkinsonian patients with severe motor-fluctuations
002435 (1994) C. Mytilineou [États-Unis] ; P. Werner [États-Unis] ; S. Molinari [États-Unis] ; A. Di Rocco [États-Unis] ; G. Cohen [États-Unis] ; D. Yahr [États-Unis]Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease
002438 (1994) P. Vieregge [Allemagne]Genetic factors in the etiology of idiopathic Parkinson's disease
002450 (1994) A. Espino [Espagne] ; S. Ambrosio [Espagne] ; R. Bartrons [Espagne] ; G. Bendahan [Espagne] ; M. Calopa [Espagne]Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+
002499 (1993) H. Baas [Allemagne] ; K. Stecker [Allemagne] ; A. Fischer [Allemagne]Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease
002501 (1993) M. Pinter [Autriche] ; J. Helscher [Autriche]Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease
002506 (1993) T. Klockgether [Allemagne] ; P. Jacobsen [Danemark] ; -A. Löschmann [Allemagne] ; L. Turski [Allemagne]The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist
002512 (1993) K. Vrecko [Autriche] ; D. Birkmayer [Autriche] ; J. Krainz [Autriche]Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH)
002513 (1993) J. Helscher [Autriche] ; M. Pinter [Autriche]Speed and power of higher cerebral functions in parkinsonian patients
002516 (1993) M. Wu [Taïwan] ; C. Chiu [Taïwan] ; M. Wang [Taïwan] ; C. Chen [Taïwan]Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease
002522 (1993) E. Fertl [Autriche] ; A. Doppelbauer [Autriche] ; E. Auff [Autriche]Physical activity and sports in patients suffering from Parkinson's disease in comparison with healthy seniors
002532 (1993) M. Palmer [États-Unis] ; T. Dekosky [États-Unis]Monoamine neurons in aging and Alzheimer's disease
002533 (1993) H. Tohgi [Japon] ; T. Abe [Japon] ; S. Takahashi [Japon] ; J. Takahashi [Japon] ; Y. Nozaki [Japon] ; M. Ueno [Japon] ; T. Kikuchi [Japon]Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes
002537 (1993) R. Volpi [Italie] ; P. Caffarra [Italie] ; A. Scaglioni [Italie] ; A. Saginario [Italie] ; D. Maestri [Italie] ; S. Vourna [Italie] ; P. Vescovi [Italie] ; P. Chiodera [Italie] ; V. Coiro [Italie]Lack of ACTH/cortisol and GH responses to intravenously-infused substance P in Parkinson's disease
002540 (1993) S. Markus [Royaume-Uni] ; M. Tomkins [Royaume-Uni] ; M. Stern [Royaume-Uni]Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters
002543 (1993) T. Greenamyre [États-Unis]Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease
002544 (1993) J. Kornhuber [Allemagne] ; M. Weller [Allemagne] ; P. Riederer [Allemagne]Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis
002549 (1993) H. Heinonen [Finlande] ; M. Savij Rvi [Finlande] ; M. Kotila [Finlande] ; A. Hajba [Finlande] ; M. Scheinin [Finlande]Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
002552 (1993) H. Youdim [Israël] ; P. Riederer [Allemagne]Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition
002561 (1993) E. Fertl [Autriche] ; E. Auff [Autriche] ; A. Doppelbauer [Autriche] ; F. Waldhauser [Autriche]Circadian secretion pattern of melatonin in de novo Parkinsonian patients: evidence for phase-shifting properties of l-dopa
002565 (1993) W. Olanow [États-Unis]A scientific rationale for protective therapy in Parkinson's disease
002567 (1993) G. Arnold [Allemagne] ; B. Bondy [Allemagne] ; O. Bandmann [Allemagne] ; Th. Gasser [Allemagne] ; J. Schwarz [Allemagne] ; C. Trenkwalder [Allemagne] ; M. Wagner [Autriche] ; Werner Poewe [Autriche, Allemagne] ; H. Oertel [Allemagne]3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes
002611 (1992) J. Málly [Hongrie]Some new aspects of the effect of (−)deprenyl in Parkinson's disease—a retrospective study
002617 (1992) M. Pinter [Autriche] ; J. Helscher [Autriche] ; J. Nasel [Autriche] ; E. Riedl [Autriche] ; G. Schnaberth [Autriche]Quantification of motor deficit in Parkinson's disease with a motor performance test series
002619 (1992) H. Karbe [Allemagne] ; V. Holthoff [Allemagne] ; M. Huber [Allemagne] ; K. Herholz [Allemagne] ; K. Wienhard [Allemagne] ; R. Wagner [Allemagne] ; -D. Heiss [Allemagne]Positron emission tomography in degenerative disorders of the dopaminergic system
002626 (1992) P. Hartikainen [Finlande] ; J. Reinikainen [Finlande] ; H. Soininen [Finlande] ; J. Sirviö [Finlande] ; R. Soikkeli [Finlande] ; J. Riekkinen [Finlande]Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls
002639 (1992) H. Soininen [Finlande] ; -L. Helkala [Finlande] ; V. Laulumaa [Finlande] ; R. Soikkeli [Finlande] ; P. Hartikainen [Finlande] ; J. Riekkinen [Finlande]Cognitive profile of Alzheimer patients with extrapyramidal signs: A longitudinal study
002699 (1991) D. Prell [États-Unis] ; K. Khandelwal [États-Unis] ; S. Burns [États-Unis] ; P. Blandina [États-Unis] ; M. Morrishow [États-Unis] ; P. Green [États-Unis]Levels of pros -methylimidazoleacetic acid: Correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i -k "1435-1463" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i  \
                -Sk "1435-1463" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    ISSN.i
   |clé=    1435-1463
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024